Zydus Lifesciences Ltd

NSE: ZYDUSLIFE · BSE: 532321 · Pharmaceuticals & Biotechnology · 88 announcements

Zydus Lifesciences Ltd news stories on ALFA NewsRead the news →

Share price: ₹1,199.50
Market cap: ₹1,20,698 Cr
Revenue (annual): ₹27,148 Cr
Net profit (annual): ₹5,040 Cr
P/E (TTM): 28.9×Sector 43.8×
Promoter holding: 75.01%+0.00% QoQ
FII holding: 7.05%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Other Announcement 3 Business Update 3 Acquisition 3 Earnings Call 2 Results Update 1 Regulatory Approval 1 Product Launch 1 Partnership 1 Merger & Restructuring 1 Management Change 1 Financial Results 1 Capital Structure Change 1 Capacity Expansion 1 Board Meeting Date 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements with these filters

4 Nov 2026 19:15 IST NSE

Earnings Call

Zydus Lifesciences Earnings Call Transcript: Key Takeaways

Consolidated revenue ₹7,910 Cr (+29% YoY), EBITDA margin 24%, net profit ₹930 Cr. Growth partly acquisition-led. Saroglitazar launch spend is heavy and the US launch is targeted for March 2027.

Open call summary → Read the filing ↗

4 Nov 2026 12:35 IST NSE

Earnings Call

Zydus Lifesciences Investor Presentation: Key Takeaways

Q2 FY27 revenue Rs 7,910 Cr (+29% YoY), EBITDA Rs 1,895 Cr at 24.0% margin, reported PAT Rs 926 Cr (-26.6% YoY). Branded India and North America drove growth; FX and D&A weighed on profit.

Open call summary → Read the filing ↗